No headlines found.
Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025
Globe Newswire (Wed, 19-Nov 4:20 PM ET)
Vivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference Call
Globe Newswire (Wed, 19-Nov 8:30 AM ET)
Globe Newswire (Tue, 30-Sep 8:30 AM ET)
Globe Newswire (Wed, 17-Sep 8:30 AM ET)
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
Vivos Therapeutics trades on the NASDAQ stock market under the symbol VVOS.
As of December 12, 2025, VVOS stock price declined to $2.07 with 115,630 million shares trading.
VVOS has a beta of 0.87, meaning it tends to be less sensitive to market movements. VVOS has a correlation of 0.02 to the broad based SPY ETF.
VVOS has a market cap of $18.61 million. This is considered a Sub-Micro Cap stock.
Last quarter Vivos Therapeutics reported $7 million in Revenue and -$.49 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.03.
In the last 3 years, VVOS traded as high as $74.05 and as low as $1.91.
The top ETF exchange traded funds that VVOS belongs to (by Net Assets): VTI, VXF, DFAC, DFSU.
VVOS has underperformed the market in the last year with a price return of -53.5% while the SPY ETF gained +14.0%. VVOS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -40.3% and -8.4%, respectively, while the SPY returned +4.0% and -0.2%, respectively.
VVOS support price is $2.01 and resistance is $2.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VVOS shares will trade within this expected range on the day.